Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database

被引:0
作者
Kenichiro Sato
Tatsuo Mano
Atsushi Iwata
Tatsushi Toda
机构
[1] University of Tokyo,Department of Neurology, Graduate School of Medicine
来源
Journal of Neuro-Oncology | 2019年 / 145卷
关键词
Neurological adverse events; Pharmacovigilance; Immune checkpoint inhibitor; JADER;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1 / 9
页数:8
相关论文
共 207 条
[1]  
Ribas A(2018)Cancer immunotherapy using checkpoint blockade Science 359 1350-1355
[2]  
Wolchok JD(2018)Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis BMJ 363 k4226-1728
[3]  
Xu C(2018)Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JAMA Oncol 4 1721-225
[4]  
Chen YP(2016)Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy Eur J Cancer 60 210-1222
[5]  
Du XJ(2017)Neurological complications associated with anti-programmed death 1 (PD-1) antibodies JAMA Neurol 74 1216-8
[6]  
Liu JQ(2017)Neurological adverse events associated with immune checkpoint inhibitors: review of the literature Eur J Cancer 73 1-385
[7]  
Huang CL(2017)Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature Ann Oncol 28 377-718
[8]  
Chen L(2018)Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management Curr Neurol Neurosci Rep 18 3-136
[9]  
Zhou GQ(2018)Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system Ther Adv Neurol Disord 11 1756286418799864-1134
[10]  
Li WF(2017)Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis Oncologist 22 709-1390